Can Hormone Therapy SHRINK Breast Ductal Carcinoma in Situ?
Research Alert! I read medical journals, so you don’t have to*…
*News FLASH -My reviews of recently published menopause research.
This study was presented as an abstract at The American Society of Clinical Oncology 2025 Annual Meeting
Abstract Title: The Promise Study: A presurgical randomized clinical trial of CE/BZA vs placebo in postmenopausal women with ductal carcinoma in situ. Link to Abstract
Lead Author: Swati Kulkarni MD
Note: I will be interviewing Dr. Kulkarni on Dr. Streicher’s Inside Information: Menopause, Midlife and More on Wednesday, June 11, 7:30 PM CST.
The Purpose of the Study
To determine if women with breast ductal carcinoma in situ (DCIS), an early form of breast cancer found in the milk ducts, can safely take a specific formulation of hormone therapy (conjugated estrogens and bazodoxifene) and what the impact would be on DCIS and quality of life.
Background
